Many Galena Biopharma, Inc.(GALE) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Galena Biopharma Inc was Downgraded by FBR & Co. on Feb 6, 2017 to Mkt Perform, Lowers Price Target to $ 4 from a previous price target of $11 .Galena Biopharma Inc was Downgraded by Maxim Group to Hold on Feb 2, 2017. Company shares were Reiterated by Maxim Group on Dec 2, 2016 to Buy, Raises Price Target to $ 4 from a previous price target of $1 .
Company has reported several Insider transactions to the SEC, on Jun 7, 2016, Ryan Dunlap (Former Chief Financial Officer) sold 126,875 shares at 2.18 per share price.
Galena Biopharma Inc Last issued its quarterly earnings results on Aug 9, 2016. The company reported $0.05 EPS for the quarter, beating the analyst consensus estimate by $ 0.11. Analyst had a consensus of $-0.06.During the same quarter in the previous year, the company posted $-0.10 EPS.
Galena Biopharma, Inc. (NASDAQ:GALE) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 3 by 4 Brokerage Firm. 4 Brokerage Firms have advised hold.
Galena Biopharma, Inc. (NASDAQ:GALE): 3 Analyst have given the stock of Galena Biopharma, Inc. (NASDAQ:GALE) a near short term price target of $5.33. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $2.31. The higher price target estimate is at $8 while the lower price estimates are fixed at $4.
Galena Biopharma, Inc. (NASDAQ:GALE) rose 0.97% or 0.0076 points on Tuesday and made its way into the gainers of the day. After trading began at $0.83 the stock was seen hitting $0.83 as a peak level and $0.76 as the lowest level. The stock ended up at $0.7879. The daily volume was measured at 2,503,939 shares. The 52-week high of the share price is $49.802 and the 52-week low is $0.72. The company has a market cap of $15 million.
Galena Biopharma, Inc. is a biopharmaceutical company that develops innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. Galena Biopharma, Inc., formally known as RXi Pharmaceuticals Corporation, is based in Portland, Oregon.